Skip to content
value.today
Lantern Pharma Inc. logo

Lantern Pharma Inc.

Total raised
$2 M
1 round on record
Latest round
$2 M
Mar 2019
First round on record
Mar 2019
Today
Went public
See the company page

Lantern Pharma Inc. is listed today as Lantern Pharma Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Lantern Pharma Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2019$2 MNo. 1$2 to $10 million

Lantern Pharma Inc.: Raise no. 1, Mar 2019

Investors in this round

5 investors had bought by the notice of Mar 18, 2019: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Lantern Pharma Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $6 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$360,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Texas

People named in the notice

  • Panna Sharma · Executive Officer, Director
  • Arunkumar Asaithambi · Director
  • David Silberstein · Director
  • Donald Keyser · Director
  • John Fucci · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “This amount consists of proceeds from the sale of Series A Preferred Stock, the sale of securities convertible into Series A Preferred Stock and future proceeds which may be realized from the exercise of warrants issued in connection with this offering.”
  • On the use of proceeds: “Portions of the proceeds will be used to make ordinary course compensation payments to the Company's employees, including the Company's CEO.”

Signed by Panna Sharma, Ceo. Source: SEC Form D, newest notice filed Mar 18, 2019. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Lantern Pharma Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2019).

    SEC Form D · Mar 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2019

That is all the official record says: Lantern Pharma Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Lantern Pharma Inc. are on record.

Investors#

19 named in official filings. Open an investor to see everything it has backed.

Investors in Lantern Pharma Inc.
InvestorKindAmountRoundRoleSource
BIOS Advisors GP, LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
BIOS Capital Management, LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Bios Equity Partners II, LPPrivate equitynot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Bios Equity Partners, LPPrivate equitynot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
BIOS Fund II, LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
BIOS Fund II NT, LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
BIOS Fund II QP, LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
BIOS Fund I, LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
BIOS Fund I QP, LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
BP Directors, LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Cavu Advisors, LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Cavu Management, LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
D. Jeffrey KeyserPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2020)SEC Form 3
GPG LPI Investment, LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Green Park & Golf Ventures II, LLCVenture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Green Park & Golf Ventures, LLCVenture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Health Wildcatters Fund II, LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Health Wildcatters, LLCOthernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Lantern 3-19 Investment, LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 5 investors.

Largest shareholders today

Institutions holding Lantern Pharma Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Lantern Pharma Inc.
NameRoleNamed in
Panna SharmaExecutive officerMar 2019
Arunkumar AsaithambiDirectorMar 2019
David SilbersteinDirectorMar 2019
Donald KeyserDirectorMar 2019
John FucciDirectorMar 2019
Panna SharmaDirectorMar 2019

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.